How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Frontotemporal Dementia Treatment Market
- By Treatment Type: Pharmacological Therapy, Non-Pharmacological Therapy, Symptomatic Treatment, Experimental Therapies, Supportive Care
- By Drug Class: Selective Serotonin Reuptake Inhibitors (SSRIs), Antipsychotics, Cholinesterase Inhibitors, NMDA Receptor Antagonists, Mood Stabilizers
- By Stage of Disease: Early Stage, Middle Stage, Late Stage
- By Mechanism of Action: Tau Protein Inhibitors, TDP-43 Protein Modulators, Neuroinflammation Modulators, Neuroprotective Agents, Synaptic Function Enhancers
- By Patient Demographics: Sporadic FTD Patients, Familial FTD Patients, Behavioral Variant FTD Patients, Primary Progressive Aphasia Patients
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Pharmacological Therapy leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 298 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.181 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.189 →
Full report · locked preview
Everything inside the Frontotemporal Dementia Treatment Market report
A complete, evidence-based study - 12 chapters and 125 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 5
Drug Class 5
Stage of Disease 3
Mechanism of Action 5
Patient Demographics 4
Companies profiled
Biogen Inc.
AbbVie Inc.
Roche Holding AG
Eli Lilly and Company
AC Immune SA
Axsome Therapeutics Inc.
Anavex Life Sciences Corp.
Cassava Sciences Inc.
TauRx Therapeutics Ltd.
Ionis Pharmaceuticals Inc.
Neurocrine Biosciences Inc.
Alzheon Inc.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Biogen Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →AbbVie Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Roche Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Eli Lilly and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →AC Immune SA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Axsome Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Anavex Life Sciences Corp.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Cassava Sciences Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →TauRx Therapeutics Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Ionis Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Neurocrine Biosciences Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Alzheon Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Cerecin Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Denali Therapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →ACADIA Pharmaceuticals Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,163M by 2033 · 11.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Pharmacological Therapy47.0
- Non-Pharmacological Therapy10.4
- Symptomatic Treatment10.9
- Experimental Therapies16.1
- Supportive Care15.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$163.2M → $363.1M · 10.5%
Europe$113.7M → $291.1M · 12.5%
Asia Pacific$103.8M → $263.6M · 12.4%
Latin America$64.3M → $148.5M · 11.0%
Middle East and Africa$49.4M → $115.0M · 11.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.242026
11.252027
11.272028
11.282029
11.282030
11.312031
11.312032
11.342033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Biogen Inc.21.5
- AbbVie Inc.18.9
- Roche Holding AG8.8
- Eli Lilly and Company8.4
- AC Immune SA4.4
- Axsome Therapeutics Inc.10.1
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type27.6%
Drug Class18.0%
Stage of Disease13.1%
Mechanism of Action24.0%
Patient Demographics17.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.7
- Europe24.6
- Asia Pacific22.3
- Latin America12.6
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Biogen Inc. | 94 | 97 | 80 | 81 | 87 | 87 | 88 |
| AbbVie Inc. | 90 | 74 | 73 | 89 | 80 | 89 | 83 |
| Roche Holding AG | 75 | 83 | 85 | 74 | 74 | 75 | 78 |
| Eli Lilly and Company | 60 | 69 | 70 | 59 | 59 | 61 | 63 |
| AC Immune SA | 71 | 62 | 73 | 52 | 61 | 63 | 64 |
| Axsome Therapeutics Inc. | 55 | 57 | 62 | 63 | 47 | 49 | 56 |
| Anavex Life Sciences Corp. | 49 | 60 | 57 | 48 | 58 | 58 | 55 |
| Cassava Sciences Inc. | 60 | 46 | 49 | 50 | 52 | 35 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Biogen Inc.
- AbbVie Inc.
- Roche Holding AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Biogen Inc. | ✓ | ✓ | ✓ | ◐ | ◐ | ✓ |
| AbbVie Inc. | ✓ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Roche Holding AG | − | ◐ | ◐ | ◐ | ◐ | ✓ |
| Eli Lilly and Company | − | ◐ | ✓ | ◐ | ◐ | − |
| AC Immune SA | ◐ | ◐ | − | − | − | ◐ |
| Axsome Therapeutics Inc. | − | − | − | ◐ | ◐ | − |
| Anavex Life Sciences Corp. | − | ◐ | ◐ | − | − | − |
| Cassava Sciences Inc. | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Biogen Inc.88
2AbbVie Inc.83
3Roche Holding AG78
4AC Immune SA64
5Eli Lilly and Company63
6Axsome Therapeutics Inc.56
7Anavex Life Sciences Corp.55
8Cassava Sciences Inc.49
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Biogen Inc.AbbVie Inc.Roche Holding AG
Contender2
Focused players with pockets of strength.
Eli Lilly and CompanyAC Immune SA
Niche3
Specialists in a single segment or region.
Axsome Therapeutics Inc.Anavex Life Sciences Corp.Cassava Sciences Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Type in North America, then scale across Frontotemporal Dementia Treatment Market — a $256M beachhead inside a $4.31B market.
Beachhead (SOM)$256Mobtainable near-term
Serviceable (SAM)$1.80Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Pharmacological Therapy
Best fit — highest urgency & budget in Treatment Type.
Economic buyer80 fit
Non-Pharmacological Therapy
Strong fit — clear ROI and a fast path to value.
End user67 fit
Symptomatic Treatment
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Class & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Stage of Disease
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel29%
Digital / self-serve23%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Frontotemporal Dementia Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified21%
Evaluation15%
Closed-won7%
$20.9KCAC
$106KLTV
5.1:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Frontotemporal Dementia Treatment Market is a resilient opportunity — $1.74B by 2033, compounding at 3.9%.
TAM · 2025$1.28Btoday
TAM · 2033$1.74Bforecast
CAGR3.9%2027–2033
Cumulative$13.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.74BTotal addressable market
SAM$609MServiceable available market
SOM$99MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.9% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.74BLarge & growingTAM by 2033 at 3.9% CAGR
$609MServiceable nowreachable with today’s model
$99MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.36BBear2.5% CAGR
$1.74BBase3.9% CAGR
$2.22BBull5.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Class optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Frontotemporal Dementia Treatment Market — a $4.31B market by 2033. Plan: grow share from 9.9% to 17.0%.
Market size · 2033$4.31Btotal addressable
Market CAGR7.2%2027–2033
Target share17.0%from 9.9% today
Revenue ambition$732Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.9% | 17.0% | Behind |
| Revenue | $418M | $732M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 31.7% | 42.8% | On track |
| Customer retention | 84.8% | 96.3% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Class capability
A defensible second engine — invest in Drug Class to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Class
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $101M capacity & capability investment
- Greenlight bolt-on M&A in Drug Class
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Frontotemporal Dementia Treatment Market conversation — a $4.97B market you can size, segment and defend in minutes.
Market size · 2033$4.97Btotal opportunity
Growth9.6%CAGR to 2033
Addressable buyers960+accounts in scope
Typical ROI6.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.2×return on cost, year one
< 4 mopayback period
$89K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Biogen Inc.AbbVie Inc.Roche Holding AGEli Lilly and CompanyAC Immune SAAxsome Therapeutics Inc.Anavex Life Sciences Corp.Cassava Sciences Inc.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Frontotemporal Dementia Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Frontotemporal Dementia Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Front-loading Mortuary Cabinet Market
Market size, share, segmentation and regional forecast.
$828M market · 2025 base year
View reportFront Loading Laboratory Autoclaves Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportFront Loading Autoclave Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportFront-Illuminated Medical Grade CMOS Image Sensor Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportFrog Splint Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportPower Meters Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportFreund's adjuvant Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportFreund Adjuvant Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportSpecimen Dividers Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportLaboratory Agitator Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportBlower Purge Regenerative Air Dryers Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportFresh Frozen Plasma Storage Freezers Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.